 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...6465666768697071727374...100101» |
- | letrozole / Generic mfg.
Review, Journal: Constitutional delay of puberty versus congenital hypogonadotropic hypogonadism: Genetics, management and updates. (Pubmed Central) - Feb 20, 2020
Other causes of DP include permanent hypogonadotropic hypogonadism, functional hypogonadotropic hypogonadism (due to chronic diseases and conditions), and gonadal failure. In this review we discuss these themes along with the latest achievements in the field of puberty research, and include a brief synopsis on the differential diagnosis and management of patients with CDGP and congenital hypogonadotropic hypogonadism.
- letrozole / Generic mfg.
Hyperandrogenic effects on female fertility and pregnancy outcome (Lorenese 7) - Feb 20, 2020 - Abstract #ISGE2020ISGE_471;
Widely used stimulation protocols for patients with hyperandrogenism and PCOS are Letrozole, Сlomiphene, as well as mini stimulation with recombinant gonadotropins...In patients with PCOS, in 70% of cases, non-receptive endometrium was detected, with premature maturation in most cases. The correct assessment of patients before the IVF treatment, as well as the preliminary preparation and normalization of hormonal levels and metabolism, positively affect the amount of mature oocytes, therefore the amount of euploid embryos and the maturity of the endometrium, significantly increase the chance of pregnancy in IVF cycles.
- letrozole / Generic mfg.
Aromatase inhibitors (AOI) in ART (HALL 8 HIPPOCRATES) - Feb 20, 2020 - Abstract #ISGE2020ISGE_467;
However, such a disruption of sex steroid synthetic pathways may have detrimental effects on the oocyte and clinical outcomes. This presentation focus on the functional endocrine changes in normal ovulatory women during COS with letrozole intervention.
- letrozole / Generic mfg.
Letrozole versus clomiphene citrate: which is better for ovulation induction? (HALL 8 HIPPOCRATES) - Feb 20, 2020 - Abstract #ISGE2020ISGE_239;
For many years, drug of choice has been CC. However, this concept has been changing, making room for the use of LTZ, especially in PCOS patients, which is already considered by many authors a drug of choice in this pathology.
- || Ibrance (palbociclib) / Pfizer
Enrollment open, Trial completion date, Trial primary completion date: LACOG1018: Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer (clinicaltrials.gov) - Feb 20, 2020
P2, N=39, Recruiting, Sponsor: Latin American Cooperative Oncology Group
However, this concept has been changing, making room for the use of LTZ, especially in PCOS patients, which is already considered by many authors a drug of choice in this pathology. Not yet recruiting --> Recruiting | Trial completion date: Feb 2021 --> Mar 2023 | Trial primary completion date: Feb 2020 --> Apr 2021
- || Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Feb 19, 2020
P2, N=55, Active, not recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting | Trial completion date: Feb 2021 --> Mar 2023 | Trial primary completion date: Feb 2020 --> Apr 2021 Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Feb 2022 | Trial primary completion date: Jan 2021 --> Mar 2020
- || everolimus / Generic mfg.
Trial completion, Combination therapy, Metastases: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Feb 17, 2020
P2, N=48, Completed, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Feb 2022 | Trial primary completion date: Jan 2021 --> Mar 2020 Active, not recruiting --> Completed
- || Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov) - Feb 17, 2020
P2, N=315, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial completion date: Oct 2022 --> Apr 2022
- | New P1 trial: POWER: Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (clinicaltrials.gov) - Feb 16, 2020
P1, N=83, Not yet recruiting, Sponsor: Trish Millard, MD
- | letrozole / Generic mfg.
Journal: Letrozole treatment of adult female mice results in a similar reproductive phenotype but distinct changes in metabolism and the gut microbiome compared to pubertal mice. (Pubmed Central) - Feb 14, 2020
Our results indicate that dysregulation of metabolism and the gut microbiome in PCOS may be influenced by the timing of androgen exposure. In addition, the minimal weight gain and lack of insulin resistance in adult female mice after letrozole treatment indicates that this model may be useful for investigating the effects of hyperandrogenemia on the hypothalamic-pituitary-gonadal axis and the periphery without the influence of substantial metabolic dysregulation.
- || letrozole / Generic mfg.
Clinical, Journal: Letrozole and human menopausal gonadotropin for ovulation induction in clomiphene resistance polycystic ovary syndrome patients: A randomized controlled study. (Pubmed Central) - Feb 14, 2020
Letrozole-induced ovulation can obtain ovulation rate and pregnancy rate similar to gonadotropin, but reduce the risk associated with treatment. It can be used as an effective ovulation option for patients with polycystic ovary syndrome who are resistant to clomiphene.
- | letrozole / Generic mfg.
Journal: Effects of letrozole combined with human menopausal gonadotrophin in ovarian stimulation for intrauterine insemination cycles. (Pubmed Central) - Feb 13, 2020
The thickness of the endometrium in the letrozole + HMG group (8.8±2.1 mm) was significantly greater than that in the letrozole group (7.3±1.6 mm). The letrozole + HMG protocol of OS in IUI can improve follicular development, increase the thickness of endometrium, significantly increase the live birth rate, but not significantly increase the multiple pregnancy rate.
- letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica, exemestane / Generic mfg.
Structure-guided design of competitive isoflavanone inhibitors of aromatase for the treatment of endometriosis (Exhibit Hall A, Pennsylvania Convention Center) - Feb 13, 2020 - Abstract #ACSSp2020ACS_Sp_16228;
Furthermore, free energy calculations quantify the inhibitor’s effectiveness using conformations generated from MD. Preliminary data has shown that several isovflavanone derivatives may be promising aromatase inhibitors.
- | letrozole / Generic mfg.
New P2 trial: Extended Letrozole Regimen Co-treatment With Gonadotropin Releasing Hormone Antagonist Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Poor Responders Undergoing IVF-ET (clinicaltrials.gov) - Feb 13, 2020
P2, N=106, Recruiting, Sponsor: Cairo University
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion, Surgery: Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Feb 12, 2020
P3, N=622, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Preliminary data has shown that several isovflavanone derivatives may be promising aromatase inhibitors. Active, not recruiting --> Completed
- Mekinist (trametinib) / Novartis, paclitaxel / Generic mfg.
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib in Patients with Recurrent or Progressive Low-Grade Serous Ovarian or Peritoneal Cancer (Metro Toronto Convention Centre - 718) - Feb 11, 2020 - Abstract #SGO2020SGO_211;
Patients were randomized 1:1 to receive either TRAM 2 mg daily or 1 of 5 SOC options (weekly paclitaxel, PLD, topotecan, letrozole, or tamoxifen) until disease progression. Compared to physician’s choice SOC, TRAM was associated with significantly improved PFS and ORR in women with recurrent LGSOC.
- | Trial completion date, Trial primary completion date: STAPOVER: Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (clinicaltrials.gov) - Feb 10, 2020
P3, N=50, Not yet recruiting, Sponsor: Gynaecologisch Oncologisch Centrum Zuid
Compared to physician’s choice SOC, TRAM was associated with significantly improved PFS and ORR in women with recurrent LGSOC. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Enrollment change, PD(L)-1 Biomarker, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Feb 10, 2020
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Aug 2023 Recruiting --> Active, not recruiting | N=56 --> 30
- | Biomarker, Enrollment change, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Feb 10, 2020
P2, N=4000, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Recruiting --> Active, not recruiting | N=56 --> 30 N=1920 --> 4000
- |||| letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Clinical: Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial https://t.co/BK67wUgDKh (Twitter) - Feb 9, 2020
- | letrozole / Generic mfg., flutamide / Generic mfg.
Preclinical, Journal: Activation of androgen receptors protects intact male mice from memory impairments caused by aromatase inhibition. (Pubmed Central) - Feb 7, 2020
Co-administration of both drugs blocked object placement and object recognition memory consolidation, demonstrating that letrozole impairs memory in intact males only if androgen receptors are blocked. Together, these data suggest that DH-synthesized E and androgen receptor activation may work in concert to mediate memory consolidation in intact males, such that androgen receptor activation protects against memory impairments caused by aromatase inhibition.
- || letrozole / Generic mfg.
Clinical, Journal: Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. (Pubmed Central) - Feb 7, 2020
Women with preexisting pain have significantly higher pain values. The main increase in pain values takes place during the first 6 months of treatment.
- | letrozole / Generic mfg.
Journal: Mesenchymal stem cells derived exosomal miR-323-3p promotes proliferation and inhibits apoptosis of cumulus cells in polycystic ovary syndrome (PCOS). (Pubmed Central) - Feb 7, 2020
Real-time PCR, western blots, MTT assays, flow cytometry, luciferase reporter assays and a letrozole-induced PCOS mouse model were used to identify mechanisms of exosomal miR-323-3p on CCs...The results demonstrated that exosomal miR-323-3p promoted cell proliferation and inhibited apoptosis in CCs through targeting PDCD4 in PCOS. This study provides insight into developing new therapeutic strategies for PCOS.
- letrozole / Generic mfg.
Pilot Study Using Aromatase Inhibitor in Puberty of Boys With Partial Androgen Insensitivity: Report of Three Cases. (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_2504;
None reported significant side effects. Cases 1 and 2 are brothers (p.Ala596Tre).
- Anthropometric and Reproductive Outcomes of Patients with Gonadotropin-Independent Precocious Puberty Due to McCune-Albright Syndrome After Treatment with Distinct Therapeutic Agents (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_2478;
All patients were treated with one or more of the following agents: tamoxifen, medroxyprogesterone acetate, aromatase inhibitors (anastrozole or letrozole) and anti-androgens (cyproterone), and, in cases with secondary gonadotropic axis activation, depot GnRHa was used...Tamoxifen plus medroxyprogesterone, or cyproterone, or leuprorelin were used (each one) as the first choice in 1 patient (7.6%)...Despite a reasonable number of treatment options for peripheral PP in MAS, none of them showed proven effective results in stopping vaginal bleeding, reduce pubertal progression and preserving potential genetic adult height. Therefore, due to the extremely heterogeneous nature of PPP of MAS, the clinical treatment remains a challenge.
- letrozole / Generic mfg.
Dissecting the Relative Role of Estrogen and Androgen in Fibrosis, Skeletal Muscle Atrophy, and Inguinal Hernia Formation (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_1823;
Our findings will constitute a starting point for dissecting the relative roles of estrogen and androgen action in inguinal hernia development. This has the potential to facilitate drug development to prevent and treat hernias, especially recurrent hernias after primary hernia repairs in vulnerable populations such as elderly men.
- letrozole / Generic mfg., Faslodex (fulvestrant) / AstraZeneca
A Prospective Non-surgical Treatment for Inguinal Hernias (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_1822;
Ablation of estrogen production or its signaling not only completely prevents this phenotype but also reverses mild to moderate-sized hernias. Our findings pave the pathway for developing the first potential preventive and therapeutic pharmacological approach for combating recurrent inguinal hernias in elderly men through modulation of estrogen signaling in abdominal muscle tissue.
- | Trial completion date, Trial primary completion date, Surgery: Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery (clinicaltrials.gov) - Feb 7, 2020
P3, N=3697, Active, not recruiting, Sponsor: Gruppo Italiano Mammella (GIM)
Our findings pave the pathway for developing the first potential preventive and therapeutic pharmacological approach for combating recurrent inguinal hernias in elderly men through modulation of estrogen signaling in abdominal muscle tissue. Trial completion date: Jul 2018 --> Jul 2020 | Trial primary completion date: Jul 2018 --> Jul 2020
- ||| Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date, Surgery: DxCARTES: Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 - (clinicaltrials.gov) - Feb 7, 2020
P2, N=66, Completed, Sponsor: MedSIR
Trial completion date: Jul 2018 --> Jul 2020 | Trial primary completion date: Jul 2018 --> Jul 2020 Recruiting --> Completed | Trial completion date: May 2021 --> Dec 2019
- | New trial, Metastases: Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy (clinicaltrials.gov) - Feb 6, 2020
P, N=760, Completed, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | samotolisib (LY3023414) / Eli Lilly
Trial completion date, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Feb 5, 2020
P1, N=156, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Completed | Trial completion date: May 2021 --> Dec 2019 Trial completion date: Mar 2020 --> Dec 2020
- | letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation (clinicaltrials.gov) - Feb 5, 2020
P2/3, N=1, Completed, Sponsor: Greater Baltimore Medical Center
Trial completion date: Mar 2020 --> Dec 2020 Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Feb 2019 | Trial primary completion date: Sep 2019 --> Feb 2019
- | Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Surgery: PLATO: PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate (clinicaltrials.gov) - Feb 5, 2020
P2, N=122, Recruiting, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Feb 2019 | Trial primary completion date: Sep 2019 --> Feb 2019 Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> Dec 2025 | Initiation date: May 2019 --> Nov 2019 | Trial primary completion date: May 2021 --> Dec 2021
- | fulvestrant / Generic mfg.
New P2 trial: Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study (clinicaltrials.gov) - Feb 4, 2020
P2, N=124, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | Retrospective data, Journal, HEOR: Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis. (Pubmed Central) - Jan 30, 2020
Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> Dec 2025 | Initiation date: May 2019 --> Nov 2019 | Trial primary completion date: May 2021 --> Dec 2021 The findings of this study will be published in a peer-reviewed journal.
- || metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Jan 27, 2020
P2, N=62, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
The findings of this study will be published in a peer-reviewed journal. Trial primary completion date: Oct 2019 --> Oct 2020
- | letrozole / Generic mfg.
Trial initiation date: LEFT: Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Jan 27, 2020
P4, N=242, Not yet recruiting, Sponsor: CRG UZ Brussel
Trial primary completion date: Oct 2019 --> Oct 2020 Initiation date: Oct 2019 --> Apr 2020
- Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg., Faslodex (fulvestrant) / AstraZeneca
A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Gbrcamutation Status (Room A2) - Jan 25, 2020 - Abstract #DKK2020DKK_2054;
The results of this real-world study suggest that treatment outcomes with CDK4/6 inhibitors may be poorer in patients with gBRCAm compared with gBRCAwt disease. These findings indicate a higher unmet need among patients with gBRCAm, potentially requiring alternative treatment options.
- ||| Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal, Adverse events: Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events. (Pubmed Central) - Jan 24, 2020
Our patient's drug reaction occurred 2 months after starting the anastrozole and improved after a course of oral and topical corticosteroids. She was able to be switched to an alternate aromatase inhibitor without a recurrence of her adverse skin reaction.
- || letrozole / Generic mfg.
Clinical, Journal: Frozen embryo transfer: Endometrial preparation by letrozole versus hormone replacement cycle: A randomized clinical trial. (Pubmed Central) - Jan 24, 2020
The clinical pregnancy rate was 38.7 in the letrozole group, higher than the HR group (25.3) but not significantly different (P = 0.06). For endometrial preparation in women with a normal cycle, letrozole yields higher pregnancy rate although it is not significant; due to its cost, ease in use, and lower side effects, letrozole is a good choice.
- | letrozole / Generic mfg.
Preclinical, Journal: Establishment of partner preference in male rats: Effect of prenatal letrozole and sexual experience. (Pubmed Central) - Jan 23, 2020
These data support the idea that copulation is crucial for developing a female preference in control animals. The results suggest that brain changes produced by estrogens along early development and stimuli coming from the partner are essential for shaping sex preference.
- | Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jan 22, 2020
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
The results suggest that brain changes produced by estrogens along early development and stimuli coming from the partner are essential for shaping sex preference. Trial primary completion date: Dec 2020 --> Dec 2025
- || Imlygic (talimogene laherparepvec) / Amgen
Enrollment open: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (clinicaltrials.gov) - Jan 22, 2020
P1b, N=25, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Dec 2020 --> Dec 2025 Not yet recruiting --> Recruiting
- || Ibrance (palbociclib) / Pfizer
Enrollment open, Combination therapy: PROMETEO II: Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy (clinicaltrials.gov) - Jan 22, 2020
P1, N=20, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
Journal: Testicular estradiol and the pattern of Sertoli cell proliferation in prepuberal bulls. (Pubmed Central) - Jan 21, 2020
To evaluate the regulatory role of testicular estrogens, Jersey bull caves were treated twice weekly with the aromatase inhibitor, letrozole, from 2 to 22 wk of age and control animals were treated with the canola oil vehicle...Inhibition of aromatase had no effect on testosterone or circulating LH; testosterone increased with age as expected. Inhibition of aromatase and consequent reduced testicular estradiol did not alter Sertoli cell numbers.
- | Kisqali (ribociclib) / Novartis
Trial completion date: CORALLEEN: Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. (clinicaltrials.gov) - Jan 21, 2020
P2, N=106, Active, not recruiting, Sponsor: SOLTI Breast Cancer Research Group
Inhibition of aromatase and consequent reduced testicular estradiol did not alter Sertoli cell numbers. Trial completion date: Nov 2019 --> Nov 2020
- | Decadron (dexamethasone) / Merck (MSD)
Journal: Are testicular cortisol and WISP2 involved in estrogen-regulated Sertoli cell proliferation? (Pubmed Central) - Jan 18, 2020
Local administration beginning at 1.5 weeks of age (osmotic pump and catheter (n = 3) or a silastic implant (n = 5)) reduced Sertoli cell numbers at 6.5 weeks of age compared with littermates that received the vehicle treatment (P< 0.05). In summary, testicular glucocorticoid concentration was inversely correlated with Sertoli cell numbers during the first wave of Sertoli cell proliferation.
- | metformin / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal: Regulation of estrous cycle by Cynodon dactylon in letrozole induced polycystic ovarian syndrome in Wistars albino rats. (Pubmed Central) - Jan 18, 2020
There was a rapid decrease in the body mass as well as reproductive organs among the treatment and referral group compared to that of induced and control. Finding of this study suggests that C. dactylon treats PCOS better than metformin.
- | Targretin oral (bexarotene oral) / ReXceptor
Journal: Retinoid X receptor-mediated neuroprotection via CYP19 upregulation and subsequent increases in estradiol synthesis. (Pubmed Central) - Jan 16, 2020
Taken together, RXR stimulation can protect neurons via enhanced synthesis of estradiol with antioxidative mechanisms. The RXR-estrogen axis might be a novel mechanism-based strategy to prevent or ameliorate ischemic and/or inflammatory neuronal disorders.
- letrozole / Generic mfg.
Extracorporeal retrieval and vitrification of oocytes for fertility preservation () - Jan 16, 2020 - Abstract #Fertility2020FERTILITY_265;
Method(s): Ovarian stimulation of patient using flare protocol with 450IU of Menotrophin (FSH/LH) and letrozole...No ovarian cortex tissue cryopreserved, oophorectomized tissue sent to histology post-aspiration. Conclusion(s): This case demonstrates that extracorporeal oocyte retrieval in patients with ovarian cancer can lead to successful fertility preservation without the risk of malignant cell spillage and cancer upstaging.